ACUTAAS3,458.40

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹28,314 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation16.126.636.0
+ Finance Costs5.96.23.1
+ Interest Income-2.2-10.8-8.5
+ Dividend Income0.0-0.00.0
+ Share-based Payments2.30.00.0
+ Unrealised FX (Gain) / Loss-4.2-6.1-16.0
+ Other Non-cash Items0.33.02.6
+ Other — Cash Effects are Investing / Financing0.00.0-0.0
+ Other Reconciling Items0.00.0-3.0
Changes in Working Capital
+ Inventories-35.1-23.2-51.4
+ Trade Receivables — Current30.0-80.1-55.5
+ Other Financial Assets — Current1.0-3.0-3.7
+ Other Financial Assets — Non-current31.80.00.0
+ Other Current Assets-28.45.210.2
+ Other Non-current Assets-0.20.00.0
+ Trade Payables — Current23.621.4-2.1
+ Other Current Liabilities24.9-2.81.0
+ Provisions — Current1.912.48.4
Cash from Operating Activities
Profit Before Tax (per I/S)81.9216.2482.7528.6
+ Total Adjustments (incl. Working Capital)67.6-51.1-79.0
Cash from Operations (pre-tax)149.5165.1403.7
+ Income Taxes Paid24.346.7111.6
Cash from Operating Activities125.2118.3292.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)280.4194.6328.0
+ Acq of Investment Property66.00.00.0
+ Acq of Other Long-term Assets34.30.00.0
+ Investment in Partnership Firms / LLPs0.00.00.9
+ Loans & Advances Repaid13.00.00.0
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing2.310.88.5
+ Other Inflows / (Outflows) — Investing0.0-40.154.4
Cash from Investing Activities-365.4-223.9-265.9
Cash from Financing Activities
+ Proceeds from Issue of Shares51.9499.40.0
+ Proceeds from Borrowings218.10.018.3
+ Repayment of Borrowings0.0208.50.0
+ Payment of Lease Liabilities0.00.30.7
+ Interest Paid5.96.21.3
+ Dividends Paid10.912.312.3
+ Other Inflows / (Outflows) — Financing-13.7-11.00.0
Cash from Financing Activities239.4261.14.1
Net Changes in Cash (pre-FX)-0.9155.530.3
+ Effect of FX Rate Changes on Cash0.00.00.0
Net Changes in Cash-0.8155.530.3
Closing Cash29.7185.2
Reference Items
EBITDA128.5232.1480.4542.6
EBITDA Margin %17.9123.0535.8737.12
Free Cash Flow (CFO − Capex)-155.2-76.3-35.8-35.8
Free Cash Flow to Equity-291.0-18.8
Free Cash Flow per Basic Share-18.95-9.32-4.37-4.37
Cash Flow to Net Income2.570.740.82
Cash Paid for Taxes24.346.7111.6
Cash Paid for Interest5.96.21.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.